Parkinson's Disease

CENTRAL NERVOUS SYSTEM

Porsolt offers models in all areas of psychopharmacology, epilepsy, sleep-wake, and neurodegenerative disorders. We are uniquely placed to offer a full range of CNS efficacy and safety pharmacology assessments, from basic models and regulatory tests, through the evaluation of abuse and dependence liability and proconvulsant risk using EEG.

Parkinson's Disease

Parkinson's diseases (PD) usually appear later in life, typically in people older than 50 years of age. PD is primarily a movement disorder accompanied, in some cases, by memory impairments.

Parkinson’s disease

EARLY PHASE

LATE PHASE

Mild cognitive impairment

Slight motor impairments

Dementia in most of cases

Marked motor impairments

In vitro models - Parkinson's disease

Fluofarma, our subsidiary, supports drug discovery projects targeting Parkinson's disease and related disorders:

 - 6-OHDA-induced toxicity in SH-SY5Y cells

 - 6-OHDA-induced toxicity in ICell® DopaNeurons  (neurite outgrowth of dopamine neurons)

 - Rotenone-induced toxicity in rat mesencephalic cultures (neurite outgrowth of dopamine neurons

in vivo models - Parkinson's disease

> Suggested approach
- Neuroprotection: Treatments administered a few hours after lesion and/or chronically during 15 days.
- Improvement of motor symptoms: Treatments administered acutely on the testing day.

> Other avalaible tests:
- Screening: Evaluation of the number of contralateral rotations
- Side effects induced by repeated L-DOPA administrations: Evaluation of dyskinesias
- Lesion size induced by 6-OHDA: Evaluation of TH immunoreactivity

Dowload our latest posters: